Estrella Immunopharma announced on June 5, 2025, the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial. This trial is evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL).
The addition of a new clinical site is expected to facilitate patient enrollment and accelerate the overall progress of the trial. Expanding the number of active sites can help meet recruitment targets more efficiently.
This operational milestone demonstrates the company's commitment to advancing its lead clinical program. It is a key step in moving EB103 closer to potential regulatory approval and commercialization.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.